4//SEC Filing
Title 19 Promis 4
Accession 0001104659-25-071857
CIK 0001374339other
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 8:18 PM ET
Size
18.8 KB
Accession
0001104659-25-071857
Insider Transaction Report
Form 4
Title 19 Promis
Other
Transactions
- Exercise of In-Money
Common Shares, no par value
2025-07-25+119,800→ 2,195,429 total - Exercise of In-Money
Common Shares, no par value
2025-07-25+119,800→ 2,435,029 total - Exercise of In-Money
Tranche B Common Share Purchase Warrants
2025-07-25−119,800→ 345,316 total→ Common Shares (119,800 underlying) - Purchase
Warrants to Purchase Common Shares
2025-07-29+539,100→ 539,100 total→ Common Shares (539,100 underlying) - Exercise of In-Money
Common Shares, no par value
2025-07-25+119,800→ 2,315,229 total - Exercise of In-Money
Tranche A Common Share Purchase Warrants
2025-07-25−119,800→ 345,316 total→ Common Shares (119,800 underlying) - Exercise of In-Money
Tranche C Common Share Purchase Warrants
2025-07-25−119,800→ 345,316 total→ Common Shares (119,800 underlying)
Footnotes (4)
- [F1]On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
- [F2]On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
- [F3]On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
- [F4]On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.
Documents
Issuer
ProMIS Neurosciences Inc.
CIK 0001374339
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0002005531
Filing Metadata
- Form type
- 4
- Filed
- Jul 28, 8:00 PM ET
- Accepted
- Jul 29, 8:18 PM ET
- Size
- 18.8 KB